Clinical trials: Pediatric All, open to volunteers
Acute Lymphoblastic Leukemia, Pediatric
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
This study aims to compare the effects of two different conditioning regimens on patients with acute lymphoblastic leukemia (ALL) undergoing haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT): Total…
- Trial name
- NCT06559345
- Testing
- TMLI, TBI, Cyclophosphamide
- Where
- China
- Volunteers
- 276 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Pediatric ALL, Cardiac Defect
Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children
This multisite study seeks to understand whether and how pulse oximeter accuracy varies across children with different skin colors in real world clinical settings.
- Trial name
- PACH (NCT06529575)
- Where
- 3 sites in United States
- Volunteers
- 650 people
- Sponsor
- University of Pennsylvania
Relapse/Refractory B-cell Acute Lymphoblastic Leukemia
Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
The goal of this clinical trial is to evaluate the safety and efficacy of CD19 CAR-T cells in pediatric patients of all genders, aged 2 to 18 years, with relapsing or refractory B cell acute lymphoblastic leukemia (r/r B-ALL).
- Trial name
- NCT06635330
- Testing
- anti-CD19 CAR T cell therapy
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Kara Yakhteh Tajhiz Azma Company
Leukemia, Acute Leukemia
Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)
Acute lymphoblastic leukemia (ALL) is the most common cancer in children and, along with lymphoblastic lymphoma, represents the most common group of childhood lymphoid malignancies.
- Conditions
- Leukemia, Acute Leukemia, Acute Lymphoid Leukemia, Lymphoblastic Lymphoma
- Trial name
- STEP-ALL (NCT07634653)
- Testing
- Exercises
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Lymphatic Leukemia, Lymphoma
More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
In this study, we investigate the cardiopulmonary health of survivors who underwent cancer treatment for acute lymphoblastic leukemia (ALL) or lymphoma during childhood, compared with healthy controls.
- Trial name
- MaximALL (NCT07705178)
- Testing
- QOL assessment, Neuropsychological, Spirometry, DLCO measurement
- Where
- Germany
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School
Leukemia (Both ALL and AML), Brain Tumors
Efficacy of a Smart Holistic Health Care Platform Intervention on Cancer Children and Parents' Bio-Psycho-Social and Spiritual Health
This multicenter randomized controlled trial aims to develop and evaluate two Smart Holistic Health Care Platforms (SHHCPs) for families of children with cancer in Taiwan: the Parent Smart Holistic Health Care Platform (P-SHHCP)…
- Trial name
- NCT07805096
- Testing
- Parent Smart Holistic Health Care Platform (P-SHHCP), Child Smart Holistic Health Care Platform (C-SHHCP)
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Defense Medical University, Taiwan
Breakthrough Pain, Palliative Medicine
Paediatric Breakthrough Pain Assessment
Many children and young people with life-limiting and life-threatening illnesses get sudden bursts of pain called breakthrough pain. At the moment, there aren't any good ways to measure this pain in children and young people.
- Conditions
- Breakthrough Pain, Palliative Medicine, Oncology Pain, Pediatric ALL
- Trial name
- BEACON (NCT06790719)
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- University of Southampton
T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
To learn if giving the study drugs calaspargase pegol-mknl and decitabine in combination with venetoclax can help to control relapsed/refractory T-ALL and T-LLy. The safety of this drug combination will also be studied.
- Trial name
- NCT06561074
- Testing
- Decitabine, Venetoclax, Calaspargase pegol-mknl
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Cardiopulmonary Arrest, Pediatric ALL
Impact of a mHealth Supportive Tool on Cardiopulmonary Resuscitation' Situational Awareness
This study will be a prospective, single-center, randomized controlled trial in a tertiary pediatric emergency department with two parallel groups of voluntary pediatric physicians and nurses.
- Conditions
- Cardiopulmonary Arrest, Pediatric ALL, Resuscitation
- Trial name
- InterFACE (NCT04464603)
- Testing
- InterFACE (mHealth tool), Conventional methods
- Where
- Switzerland
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pediatric Clinical Research Platform
Hearing Loss, Hearing Loss, Sensorineural
Cochlear Implant Recipients: Comprehensive Longitudinal Evaluation
This study aims to assess hearing and speech perception, as well as quality of life, in deaf patients of all ages before and after cochlear implantation, and to explore differences across age groups and treatment subtypes…
- Conditions
- Hearing Loss, Hearing Loss, Sensorineural, Deafness, Cochlear Implantation
- Trial name
- CIRCLE (NCT07380269)
- Testing
- Cochlear Implantation
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Eye & ENT Hospital of Fudan University
T-cell Lymphoblastic Lymphoma
Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
T-cell lymphoblastic lymphoma (T-LBL) is the second most common subtype of non-Hodgkin lymphoma (NHL) in children and adolescents. With current treatment, event-free survival (EFS) rates vary between 75%~85%.
- Trial name
- NCT05681260
- Testing
- Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Children's Cancer Group, China
B Cell Precursor Acute Lymphoblastic Leukemia, Pediatric
NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL
The goal of this clinical trial is to determine whether pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients with negative deep minimal residue disease (MRD) can benefit from blinatumomab treatment.
- Conditions
- B Cell Precursor Acute Lymphoblastic Leukemia, Pediatric, Minimal Residual Disease, Next Generation Sequencing (NGS)
- Trial name
- NCT06763302
- Testing
- Blinatumomab
- Volunteers
- 1,220 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Relapsed Pediatric ALL, Hematopoietic Cell Transplantation
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-risk CD19 positive leukemia ALL.
- Conditions
- Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy
- Trial name
- NCT07257419
- Testing
- Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- St. Jude Children's Research Hospital
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
- Conditions
- Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric
- Trial name
- NCT03628612
- Testing
- AUTO CAR T cell therapy
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 500 people
- Sponsor
- Autolus Limited
Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Building upon the results from the CCCG-ALL-2015, CCCG-ALL-2020 multicenter study cohort, concurrent research findings, and the latest clinical trials, the CCCG-ALL-2025 I/HR-B-ALL is thus developed to further improve the…
- Conditions
- Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
- Trial name
- CCCG-I/HR-ALL (NCT06764238)
- Testing
- Blinatumomab (Group A), Venetoclax (nonRand Group), Blinatumomab (Group B)
- Where
- 27 sites in China, Hong Kong
- Volunteers
- 1,800 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoblastic Leukemia, Obesity
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
The purpose of this study is determine the effectiveness of a six-month virtually-delivered dietary education intervention (PEDALL) on the prevention of overweight and obesity (OW/OB) during maintenance chemotherapy in children…
- Trial name
- PEDALL (NCT05963971)
- Testing
- PEDALL, Standard of care
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- Columbia University
Cerebral Palsy, Mobile Phone Use
Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy
Children with cerebral palsy (CP), Gross Motor Functional Classification Scale (GMFCS) I-II will be recruited to participate in a home based physical activity intervention for 4 weeks.
- Conditions
- Cerebral Palsy, Mobile Phone Use, Pediatric ALL, Physical Disability
- Trial name
- NCT06096272
- Testing
- Augment Reality Exergames
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital Los Angeles
B-cell Acute Lymphoblastic Leukemia, Obesity
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL.
- Trial name
- IDEAL2 (NCT05082519)
- Testing
- IDEAL2 Intervention
- Where
- 16 sites in United States
- Volunteers
- 240 people
- Sponsor
- Etan Orgel
Melanoma Stage III, B-cell Non Hodgkin Lymphoma
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
- Conditions
- Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma
- Trial name
- LONGSAFE (NCT06508775)
- Testing
- MB-CART19.1, MB-CART20.1, MB-CART2019.1
- Where
- 7 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Miltenyi Biomedicine GmbH
Hematologic Malignancy, ALL, Childhood
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma.
- Conditions
- Hematologic Malignancy, ALL, Childhood, AML, Childhood, Lymphoma
- Trial name
- NCT06326463
- Testing
- Fludarabine, Cyclophosphamide, CD70-CAR T cell infusion (Autologous)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- St. Jude Children's Research Hospital